NASDAQ:RVNC - Revance Therapeutics Stock Price, Forecast & News

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Revance Therapeutics Inc (NASDAQ:RVNC) released its quarterly earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.96) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.96). The biopharmaceutical company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.40 million. View Revance Therapeutics' Earnings History.

Revance Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Revance Therapeutics.

Revance Therapeutics will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 analysts have issued 1-year target prices for Revance Therapeutics' shares. Their forecasts range from $20.00 to $39.00. On average, they expect Revance Therapeutics' share price to reach $28.71 in the next twelve months. This suggests a possible upside of 8.4% from the stock's current price. View Analyst Price Targets for Revance Therapeutics.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Revance Therapeutics.

News articles about RVNC stock have been trending negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Revance Therapeutics earned a news impact score of -2.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Revance Therapeutics.

Revance Therapeutics saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 6,590,000 shares, an increase of 9.8% from the December 31st total of 6,000,000 shares. Based on an average daily volume of 661,200 shares, the days-to-cover ratio is presently 10.0 days. Approximately 16.9% of the company's stock are short sold. View Revance Therapeutics' Current Options Chain.

Some companies that are related to Revance Therapeutics include United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Evotec (EVTCY), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), HUTCHISON CHINA/S (HCM), Blueprint Medicines (BPMC), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), SAGE Therapeutics (SAGE) and Zai Lab (ZLAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), Merck & Co., Inc. (MRK), Myovant Sciences (MYOV), Intercept Pharmaceuticals (ICPT), Bristol-Myers Squibb (BMY), Global Blood Therapeutics (GBT) and Viking Therapeutics (VKTX).

Revance Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (10.73%), Franklin Resources Inc. (7.94%), Capital World Investors (4.72%), Alliancebernstein L.P. (4.32%), Capital International Investors (2.58%) and Rice Hall James & Associates LLC (2.36%). Company insiders that own Revance Therapeutics stock include Cyril Allouche, L Daniel Browne, Lauren P Silvernail and Phyllis Gardner. View Institutional Ownership Trends for Revance Therapeutics.

RVNC stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Alliancebernstein L.P., Candriam Luxembourg S.C.A., Nisa Investment Advisors LLC, Rice Hall James & Associates LLC and Citigroup Inc.. Company insiders that have sold Revance Therapeutics company stock in the last year include Cyril Allouche and L Daniel Browne. View Insider Buying and Selling for Revance Therapeutics.

RVNC stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Perceptive Advisors LLC, Rothschild & Co. Asset Management US Inc., Capital World Investors, Alyeska Investment Group L.P., EAM Global Investors LLC, Sei Investments Co. and Knights of Columbus Asset Advisors LLC. View Insider Buying and Selling for Revance Therapeutics.

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RVNC stock can currently be purchased for approximately $26.49.

Revance Therapeutics has a market capitalization of $1.19 billion and generates $3.73 million in revenue each year. The biopharmaceutical company earns $-142,570,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis. Revance Therapeutics employs 170 workers across the globe.View Additional Information About Revance Therapeutics.

The official website for Revance Therapeutics is http://www.revance.com/.

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]